<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1651">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467931</url>
  </required_header>
  <id_info>
    <org_study_id>00132408</org_study_id>
    <nct_id>NCT04467931</nct_id>
  </id_info>
  <brief_title>ACEI or ARB and COVID-19 Severity and Mortality in US Veterans</brief_title>
  <official_title>Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Salt Lake City Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Edith Nourse Rogers Memorial Veterans Hospital</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MedStar Georgetown University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for
      COVID-19, enters type II pneumocytes using angiotensin-converting enzyme 2 (ACE2). It is
      unclear whether ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) increase,
      decrease, or have no significant effect on ACE2 expression or activity. Therefore, ACEI and
      ARB may be harmful, beneficial, or have no impact on Coronavirus Disease 2019 severity and
      mortality. The Specific Aims of this observational study are: (1) Among SARS-CoV-2-positive
      outpatients, compare all-cause hospitalization and mortality rates between: 1.1 Current users
      of a range of doses of ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 1.2 Current users of a
      range of doses of ACEI- vs. ARB-based regimens, and (2) Among those hospitalized for
      COVID-19, compare all-cause mortality between: 2.1 Current users of a range of doses of
      ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 2.2 Current users of a range of doses of
      ACEI- vs. ARB-based regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Coronavirus Disease 2019 (COVID-19) pandemic has killed &gt;129,000 Americans as of June 30,
      2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for
      COVID-19, enters type II pneumocytes using angiotensin-converting enzyme 2 (ACE2). ACE
      inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase ACE2 expression.
      Theoretically, if ACEI/ARB use increases ACE2 expression in the lungs, ACEI/ARBs could
      promote SARS-CoV-2 entry into type II pneumocytes and worsen COVID-19 infection. In contrast,
      other evidence suggests that ACEI/ARBs may mitigate virus-induced inflammatory responses in
      the lungs by upregulating ACE2-mediated generation of the vasodilator and anti-inflammatory
      protein angiotensin-(1-7), thereby preventing tissue damage. Few data exist on the direction
      or magnitude of the association between ACEI/ARB use and COVID-19 severity, and whether these
      associations differ between ACEIs and ARBs. Because ACEI/ARBs are among the most commonly
      used prescription medications, it is critical to determine if ACEI/ARB users have a
      differential risk of more severe COVID-19 infection compared to non-users. The objective of
      this study is to reduce morbidity and mortality of the COVID-19 pandemic by generating timely
      evidence on the direction and magnitude of the association between ACEI/ARB use and COVID-19
      severity and mortality.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 19, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause-Hospitalization or All-Cause Mortality</measure>
    <time_frame>Through study completion (approximately July 31, 2020).</time_frame>
    <description>For outpatient Veterans with a positive SARS-CoV-2 test (Aims 1.1 and 1.2), the primary outcome is a composite of time to all-cause hospitalization or all-cause mortality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>Through study completion (approximately July 31, 2020).</time_frame>
    <description>For Veterans hospitalized with COVID-19 (Aims 2.1 and 2.2), the primary outcome is time to all-cause mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>Through study completion (approximately July 31, 2020).</time_frame>
    <description>For aims 1 and 2, a secondary outcome will be time to intensive care unit (ICU) admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Through study completion (approximately July 31, 2020).</time_frame>
    <description>For aims 1 and 2, a secondary outcome will be duration of hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>Through study completion (approximately July 31, 2020).</time_frame>
    <description>For aim 2, a secondary outcome will be time to mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis</measure>
    <time_frame>Through study completion (approximately July 31, 2020).</time_frame>
    <description>For aim 2, a secondary outcome will be time to in-hospital dialysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gastrointestinal bleed</measure>
    <time_frame>Through study completion (approximately July 31, 2020).</time_frame>
    <description>Time to gastrointestinal bleed. This will be a negative control outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinary tract infection</measure>
    <time_frame>Through study completion (approximately July 31, 2020).</time_frame>
    <description>Time to urinary tract infection. This will be a negative control outcome.</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Hypertension</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>1.1 Outpatient SARS-CoV-2 Positive, ACEI/ARB vs non-ACEI/ARB</arm_group_label>
    <description>Among Veterans with treated hypertension and without compelling indications who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.2 Outpatient SARS-CoV-2 Positive, ACEI vs. ARB</arm_group_label>
    <description>Among Veterans with treated hypertension who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.1 COVID-19 Hospitalized, ACEI/ARB vs non-ACEI/ARB</arm_group_label>
    <description>Among Veterans with treated hypertension and without compelling indications who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.2 COVID-19 Hospitalized, ACEI vs. ARB</arm_group_label>
    <description>Among Veterans with treated hypertension who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACEI/ARB</intervention_name>
    <description>Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.</description>
    <arm_group_label>1.1 Outpatient SARS-CoV-2 Positive, ACEI/ARB vs non-ACEI/ARB</arm_group_label>
    <arm_group_label>2.1 COVID-19 Hospitalized, ACEI/ARB vs non-ACEI/ARB</arm_group_label>
    <other_name>benazepril</other_name>
    <other_name>captopril</other_name>
    <other_name>enalapril</other_name>
    <other_name>fosinopril</other_name>
    <other_name>lisinopril</other_name>
    <other_name>moexipril</other_name>
    <other_name>perindopril</other_name>
    <other_name>quinapril</other_name>
    <other_name>ramipril</other_name>
    <other_name>trandolapril</other_name>
    <other_name>azilsartan</other_name>
    <other_name>candesartan</other_name>
    <other_name>eprosartan</other_name>
    <other_name>irbesartan</other_name>
    <other_name>losartan</other_name>
    <other_name>olmesartan</other_name>
    <other_name>telmisartan</other_name>
    <other_name>valsartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-ACEI/ARB</intervention_name>
    <description>Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.</description>
    <arm_group_label>1.1 Outpatient SARS-CoV-2 Positive, ACEI/ARB vs non-ACEI/ARB</arm_group_label>
    <arm_group_label>2.1 COVID-19 Hospitalized, ACEI/ARB vs non-ACEI/ARB</arm_group_label>
    <other_name>doxazosin</other_name>
    <other_name>prazosin</other_name>
    <other_name>terazosin</other_name>
    <other_name>acebutolol</other_name>
    <other_name>nebivolol</other_name>
    <other_name>atenolol</other_name>
    <other_name>betaxolol</other_name>
    <other_name>bisoprolol</other_name>
    <other_name>metoprolol</other_name>
    <other_name>pindolol</other_name>
    <other_name>penbutolol</other_name>
    <other_name>carvedilol</other_name>
    <other_name>labetalol</other_name>
    <other_name>nadolol</other_name>
    <other_name>propranolol</other_name>
    <other_name>timolol</other_name>
    <other_name>amlodipine</other_name>
    <other_name>felodipine</other_name>
    <other_name>isradipine</other_name>
    <other_name>nifedipine</other_name>
    <other_name>nicardipine</other_name>
    <other_name>nisoldipine</other_name>
    <other_name>diltiazem</other_name>
    <other_name>verapamil</other_name>
    <other_name>clonidine</other_name>
    <other_name>guanfacine</other_name>
    <other_name>guanabenz</other_name>
    <other_name>methyldopa</other_name>
    <other_name>reserpine</other_name>
    <other_name>hydralazine</other_name>
    <other_name>minoxidil</other_name>
    <other_name>aliskiren</other_name>
    <other_name>spironolactone</other_name>
    <other_name>eplerenone</other_name>
    <other_name>bumetanide</other_name>
    <other_name>furosemide</other_name>
    <other_name>ethacrynic acid</other_name>
    <other_name>torsemide</other_name>
    <other_name>amiloride</other_name>
    <other_name>triamterene</other_name>
    <other_name>bendroflumethiazide</other_name>
    <other_name>chlorothiazide</other_name>
    <other_name>chlorthalidone</other_name>
    <other_name>hydrochlorothiazide</other_name>
    <other_name>indapamide</other_name>
    <other_name>metolazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACEI</intervention_name>
    <description>Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.</description>
    <arm_group_label>1.2 Outpatient SARS-CoV-2 Positive, ACEI vs. ARB</arm_group_label>
    <arm_group_label>2.2 COVID-19 Hospitalized, ACEI vs. ARB</arm_group_label>
    <other_name>benazepril</other_name>
    <other_name>captopril</other_name>
    <other_name>enalapril</other_name>
    <other_name>fosinopril</other_name>
    <other_name>lisinopril</other_name>
    <other_name>moexipril</other_name>
    <other_name>perindopril</other_name>
    <other_name>quinapril</other_name>
    <other_name>ramipril</other_name>
    <other_name>trandolapril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARB</intervention_name>
    <description>Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.</description>
    <arm_group_label>1.2 Outpatient SARS-CoV-2 Positive, ACEI vs. ARB</arm_group_label>
    <arm_group_label>2.2 COVID-19 Hospitalized, ACEI vs. ARB</arm_group_label>
    <other_name>azilsartan</other_name>
    <other_name>candesartan</other_name>
    <other_name>eprosartan</other_name>
    <other_name>irbesartan</other_name>
    <other_name>losartan</other_name>
    <other_name>olmesartan</other_name>
    <other_name>telmisartan</other_name>
    <other_name>valsartan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Aim 1: Positive test for SARS-CoV-2 in the outpatient setting, diagnosed with hypertension
        prior to the index date, and be treated with an antihypertensive in the 90 days prior to
        the index date.

        Aim 2: Hospitalized for COVID-19, diagnosed with hypertension prior to the index date, and
        be treated with an antihypertensive in the 90 days prior to the index date.

        ACEI/ARB vs. non-ACEI/ARB analyses (aims 1.1 and 2.1): Do not have compelling indications
        that would warrant preferential treatment with an ACEI or an ARB (i.e., diabetes, stroke,
        chronic kidney disease, heart failure with reduced ejection fraction, or coronary heart
        disease).

        ACEI vs. ARB analyses (aims 1.2 and 2.2): Not concomitantly treated with an ACEI and an ARB
        in the 90 days prior to the index date, and must be treated with at least an ACEI or an ARB
        in the 90 days prior to the index date.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive SARS-CoV-2 test in the outpatient setting (Aim 1) or hospitalized for
             COVID-19 (Aim 2)

          -  Meet continuous enrollment criteria (≥1 inpatient or any outpatient encounter in each
             of the two, six-month periods during the 365 days prior to the index date)

          -  Do not have data inconsistencies (test patients, not Veterans, multiple death dates in
             data, or not alive on index date)

          -  Diagnosed with hypertension at any point prior to the index date

          -  Had at least one prescription dispensed for an antihypertensive medication in the 90
             days prior to the index date

        Exclusion Criteria:

          -  Aim 1.1 and 2.1 (ACEI/ARB vs. non-ACEI/ARB comparison): diagnosed with a compelling
             indication for ACEI/ARB at any point prior to the index date (i.e., diabetes, stroke,
             chronic kidney disease, heart failure with reduced ejection fraction, or coronary
             heart disease)

          -  Aim 1.2 and 2.2 (ACE vs. ARB comparison): prescription fills for both an ACEI and an
             ARB in the 90 days prior to the index date; no prescription fill for an ACEI or an ARB
             in the 90 days prior to the index date
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam P Bress, PharmD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Adam Bress</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>angiotensin-converting enzyme inhibitor</keyword>
  <keyword>angiotensin receptor antagonist</keyword>
  <keyword>Veterans</keyword>
  <keyword>antihypertensive medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Felodipine</mesh_term>
    <mesh_term>Nadolol</mesh_term>
    <mesh_term>Acebutolol</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Guanfacine</mesh_term>
    <mesh_term>Minoxidil</mesh_term>
    <mesh_term>Prazosin</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Hydralazine</mesh_term>
    <mesh_term>Captopril</mesh_term>
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
    <mesh_term>Indapamide</mesh_term>
    <mesh_term>Quinapril</mesh_term>
    <mesh_term>Trandolapril</mesh_term>
    <mesh_term>Torsemide</mesh_term>
    <mesh_term>Metolazone</mesh_term>
    <mesh_term>Fosinopril</mesh_term>
    <mesh_term>Isradipine</mesh_term>
    <mesh_term>Methyldopa</mesh_term>
    <mesh_term>Eprosartan</mesh_term>
    <mesh_term>Pindolol</mesh_term>
    <mesh_term>Moexipril</mesh_term>
    <mesh_term>Reserpine</mesh_term>
    <mesh_term>Chlorothiazide</mesh_term>
    <mesh_term>Bendroflumethiazide</mesh_term>
    <mesh_term>Betaxolol</mesh_term>
    <mesh_term>Nisoldipine</mesh_term>
    <mesh_term>Guanabenz</mesh_term>
    <mesh_term>Penbutolol</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Amiloride</mesh_term>
    <mesh_term>Triamterene</mesh_term>
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Bumetanide</mesh_term>
    <mesh_term>Ethacrynic Acid</mesh_term>
    <mesh_term>Terazosin</mesh_term>
    <mesh_term>Azilsartan medoxomil</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT04467931/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

